Evaluating remission of type 2 diabetes using a metabolic intervention including fixed‐ratio insulin degludec and liraglutide: A randomized controlled trial
An intensive remission-induction intervention including fixed-ratio insulin degludec/liraglutide reduced the risk of type 2 diabetes relapse within 1 year without sustained remission.
Authors
- Faith Kirabo
- Diana Sherifali (ORCID: https://orcid.org/0000-0002-4423-3848)
- Natalia McInnes (ORCID: https://orcid.org/0000-0003-1495-3825)
- Heather Lochnan (ORCID: https://orcid.org/0000-0002-3820-7897)
- Kate Tsiplova
- Zubin Punthakee (ORCID: https://orcid.org/0000-0003-4894-3617)
- Stephanie Hall (ORCID: https://orcid.org/0000-0003-0007-0044)
- Mahua Ghosh (ORCID: https://orcid.org/0009-0006-4178-2629)
- Ronald J. Sigal (ORCID: https://orcid.org/0000-0001-8324-717X)
- Hertzel C. Gerstein (ORCID: https://orcid.org/0000-0001-8072-2836)
- Tamara Spaic (ORCID: https://orcid.org/0000-0002-7161-1752)
- Stewart B. Harris (ORCID: https://orcid.org/0000-0002-8282-5449)
- Thomas Ransom
Institutions
- Western University (CA)
- Capital District Health Authority (CA)
- Lawson Health Research Institute (CA)
- University of Ottawa (CA)
- University of Alberta (CA)
- University of Calgary (CA)
- Ottawa Hospital (CA)
- Population Health Research Institute (CA)
- Collaborative Group (United States) (US)
- McMaster University (CA)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2024-09-06
- DOI
- https://doi.org/10.1111/dom.15926
- Citations
- 6
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.15
Funders
- Novo Nordisk Foundation Center for Basic Metabolic Research